The authors studied the correlation between serum haloperidol levels and clinical response under a fixed dose haloperidol treatmentC 15mg/day) in 29 hospitalized DSM-III-R schizophrenics, 15 positive subtype and 14 negative subtype by Positive and Negative Syndrome Scale (PAN SS). Serum haloperidol levels were measured by H igh Performance Liquid Chromatography (HPLC ) on the 7th and 28th day of treatment, and positive and negative symptom scores were rated using PANSS on the baseline, 7th day and 28th day of treatment Serum haloperidol levels on the 7th day of treatment were 10.1 ± 5*5ng/ml in positive schizophrenics and 7.6土 62ng/ml in negative schizophrenics. On the 28th day serum haloperidol levels were 10.0± 5.3ng/ml in positive schizophrenics and 9.1±6.3ng/ml in negative schizophrenics. There were no significant difference in the serum haloperidol levels between positive schizophrenics and negative schizophrenics on both occasions. In positive schizophrenic subtype, positive symptom scores improved 26.7土 19.2% and negative symptom scores improved 23.4± 13.1% on the 7th day of haloperidol treatment in comparison with baseline score, and 44.6土 21.8% and 33.6土 17.3% respectively on the 28th day. In negative schizophrenic subtype, positive symptom scores improved 9.4士 10.2% and negative symptom scores improved 16.1 ± 16.5% on the 7th day of haloperidol treatment in comparison with baseline score, and 18.0±20.3% and 25.4士 14.8% respectively on the 28th day. There was cuvilinear relationship between serum haloperidol levels and positive symptom improvement rate in positive schizophrenic subtype, and serum haloperidol therapeutic range (defined by the median score of improvement) was estimated between 7.9—21.4ng/ml. There were no significant relationship between serum haloperidol levels and PANSS negative symptom improvement rate in both positive and negative schizophrenic subtypes.
서 론
대상 및 방법
결 과
고 찰
결 론
참 고 문 헌